Chemotherapy w/wo WeiLeShu in Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2022-07-11
Target enrollment:
Participant gender:
Summary
A total of 50 patients with metastatic colorectal cancer will be enrolled in the study. The
patients were randomly divided into the WLS-intervention group and the control group. The two
groups of patients were given the most appropriate medication according to the specific
conditions of the disease. Patients in the intervention group received additional oral
administration of Weileshu, a probiotics product (Tongchuang Biotechnology).